While cardiovascular death alone didn't reach statistical significance (middle-left panel), consistent directional benefits appeared across heart failure outcomes and all-cause mortality, suggesting broad cardiovascular protection
It is typically mild to moderate, dose-dependent, and tends to resolve within the first few weeks at each dose level during titration
it rewires your appetite regulation at the neurological level
The REDEFINE Trials: 2026 data shows that CagriSema achieves ~ 23% weight loss
If you've been thinking about a GLP-1 medication to help with your weight, you've probably heard two names come up again and again: semaglutide and tirzepatide
Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al